MX358864B - Polipeptidos antibacterianos quimericos. - Google Patents
Polipeptidos antibacterianos quimericos.Info
- Publication number
- MX358864B MX358864B MX2017006157A MX2017006157A MX358864B MX 358864 B MX358864 B MX 358864B MX 2017006157 A MX2017006157 A MX 2017006157A MX 2017006157 A MX2017006157 A MX 2017006157A MX 358864 B MX358864 B MX 358864B
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric
- antibacterial polypeptides
- antibacterial
- polypeptides
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones antibacterianas y métodos de fabricación y uso de las composiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1277CH2011 | 2011-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX358864B true MX358864B (es) | 2018-09-06 |
Family
ID=47009778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011853A MX347771B (es) | 2011-04-12 | 2012-04-12 | Polipeptidos antibacterianos quimericos. |
MX2017006157A MX358864B (es) | 2011-04-12 | 2012-04-12 | Polipeptidos antibacterianos quimericos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011853A MX347771B (es) | 2011-04-12 | 2012-04-12 | Polipeptidos antibacterianos quimericos. |
Country Status (7)
Country | Link |
---|---|
US (2) | US9605250B2 (es) |
EP (1) | EP2697387B1 (es) |
JP (1) | JP6243325B2 (es) |
CN (1) | CN103635584B (es) |
CA (1) | CA2833176C (es) |
MX (2) | MX347771B (es) |
WO (1) | WO2012140676A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG188566A1 (en) * | 2010-09-17 | 2013-04-30 | Tecnifar Ind Tecnica Farmaceutica S A | Antibacterial phage, phage peptides and methods of use thereof |
GB201416788D0 (en) * | 2014-09-23 | 2014-11-05 | Univ Glasgow | Therapeutic applications for pyocins |
KR20230156440A (ko) * | 2016-10-11 | 2023-11-14 | 웰스테이트 옵탈믹스 코퍼레이션 | 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질 |
EP3530674B1 (en) * | 2016-10-23 | 2024-04-24 | Denka Company Limited | Polypeptide monomer, associated product formed of said polypeptide monomer having cell penetration function, norovirus component vaccine for subcutaneous, intradermal, percutaneous or intramuscular administration and having said associated product as effective component thereof, and method for producing said associated product |
MX2019011808A (es) * | 2017-04-03 | 2020-01-09 | Sasinapas Co Ltd | Endolisinas de gram-negativas modificadas. |
US11583589B2 (en) * | 2017-08-23 | 2023-02-21 | Cygenica Limited | Cell membrane penetrating conjugates |
MX2020006191A (es) | 2017-12-14 | 2020-11-06 | Bactoclear Holdings Pte Ltd | Bacteriocinas terapeuticas. |
US11515130B2 (en) | 2018-03-05 | 2022-11-29 | Applied Materials, Inc. | Fast response pedestal assembly for selective preclean |
EP3636661A1 (en) * | 2018-10-12 | 2020-04-15 | Bioc3 | Phosphate translocator |
CN110684788B (zh) * | 2019-10-24 | 2021-07-27 | 岭南师范学院 | 金鱼c型溶菌酶亚型及其编码基因和应用 |
CN115181165B (zh) * | 2022-06-22 | 2024-04-12 | 华中农业大学 | 沙门氏菌噬菌体尾部受体结合蛋白rbp 41及其在富集与检测沙门氏菌中的应用 |
CN115322914B (zh) * | 2022-10-19 | 2024-03-22 | 天津市农业科学院 | 一种Ec-cLYZ和MEL基因共表达重组毕赤酵母的构建方法及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JPS6238172A (ja) | 1985-08-12 | 1987-02-19 | 株式会社 高研 | 抗血栓性医用材料の製造方法 |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
GB8612087D0 (en) | 1986-05-19 | 1986-06-25 | Ici Plc | Hybridisation probes |
US5017478A (en) | 1987-07-16 | 1991-05-21 | Berlex Laboratories, Inc. | Transfected cells containing plasmids having genes oriented in opposing directions and methods of using |
US5414085A (en) | 1992-04-06 | 1995-05-09 | Biosite Diagnostics, Inc. | Barbiturate derivatives and protein and polypeptide barbiturate derivative conjugates and labels |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5851802A (en) | 1996-03-22 | 1998-12-22 | Xoma Corporation | Methods for recombinant microbial production of fusion proteins and BPI-derived peptides |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
CA2349837A1 (en) * | 1998-11-18 | 2000-05-25 | Children's Hospital Medical Center | Lysozyme fusion proteins in infections |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
AU2001265425A1 (en) * | 2000-06-06 | 2001-12-17 | Pharmacal Biotechnologies, Llc | Compositions for treating biofilm |
US6913753B2 (en) | 2001-09-27 | 2005-07-05 | Gangagen, Inc. | Incapacitated whole-cell immunogenic bacterial compositions |
CN103436507B (zh) | 2006-05-05 | 2016-04-20 | 冈戈根股份有限公司 | 噬菌体衍生的抗微生物活性剂 |
IE20060488A1 (en) | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
US20100004175A1 (en) * | 2008-06-09 | 2010-01-07 | Tanya Shang | Novel bmp-12-related proteins and methods of their manufacture |
JP2012525143A (ja) | 2009-05-01 | 2012-10-22 | ルピン・リミテッド | 不溶性の組み換えタンパク質に対して溶解性を付与する新規な融合タグ |
EP2430047B1 (en) * | 2009-05-13 | 2018-03-28 | i2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
JP6034187B2 (ja) * | 2009-06-26 | 2016-11-30 | カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー | 抗微生物剤 |
-
2012
- 2012-04-12 WO PCT/IN2012/000261 patent/WO2012140676A2/en active Application Filing
- 2012-04-12 US US14/111,531 patent/US9605250B2/en active Active
- 2012-04-12 CN CN201280026193.7A patent/CN103635584B/zh active Active
- 2012-04-12 CA CA2833176A patent/CA2833176C/en active Active
- 2012-04-12 JP JP2014504452A patent/JP6243325B2/ja active Active
- 2012-04-12 MX MX2013011853A patent/MX347771B/es active IP Right Grant
- 2012-04-12 MX MX2017006157A patent/MX358864B/es unknown
- 2012-04-12 EP EP12770916.0A patent/EP2697387B1/en active Active
-
2017
- 2017-02-21 US US15/438,450 patent/US9932569B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2012140676A2 (en) | 2012-10-18 |
JP6243325B2 (ja) | 2017-12-06 |
CN103635584A (zh) | 2014-03-12 |
JP2014516358A (ja) | 2014-07-10 |
EP2697387A2 (en) | 2014-02-19 |
MX347771B (es) | 2017-05-12 |
US20140050713A1 (en) | 2014-02-20 |
CN103635584B (zh) | 2017-10-27 |
US9932569B2 (en) | 2018-04-03 |
CA2833176A1 (en) | 2012-10-18 |
CA2833176C (en) | 2023-05-16 |
US20170233706A1 (en) | 2017-08-17 |
EP2697387A4 (en) | 2015-01-07 |
EP2697387B1 (en) | 2021-09-15 |
US9605250B2 (en) | 2017-03-28 |
MX2013011853A (es) | 2014-04-30 |
WO2012140676A9 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013011853A (es) | Polipeptidos antibacterianos quimericos. | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
IN2014CN02639A (es) | ||
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
IN2015DN00127A (es) | ||
EP2728002A4 (en) | HETERODIMIZED POLYPEPTIDE | |
EP2836873A4 (en) | SWITCHING MATERIALS, AND COMPOSITIONS AND METHODS FOR MAKING THE SAME | |
LT2986726T (lt) | Naujos bacillus kamienų kompozicijos | |
EP3068222A4 (en) | Disinfectant composition | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
JO3755B1 (ar) | تركيبات تستوستيرون | |
EP3087525A4 (en) | Frequency-based reputation | |
MX2013002784A (es) | Heteroarilos fusionados y sus usos. | |
EP3013944A4 (en) | Composition of mesenchymal stem cells | |
EP3016917A4 (en) | Cement composition | |
EP2751257A4 (en) | WNT7A COMPOSITIONS AND METHOD FOR THEIR USE | |
EP3080080A4 (en) | Novel compositions | |
IN2012DN03404A (es) | ||
HK1204948A1 (en) | Radiation-sterilization-resistant protein composition | |
EP3083917A4 (en) | Detergent and rinse-aid compositions and methods | |
EP3074049A4 (en) | Novel cell-penetrating compositions and methods using same | |
EP3078375A4 (en) | Anti-fatigue composition | |
IN2012DE02272A (es) | ||
UY34613A (es) | Composición de limpieza |